FDA warns of cybersecurity risk with certain Medtronic insulin pumps

  • In Health
  • 2022-09-20 21:34:54Z
  • By Reuters

(Reuters) -The U.S. Food and Drug Administration on Tuesday warned that certain types of insulin pump systems manufactured by Medtronic were vulnerable to cyberattacks and that hackers could potentially hamper insulin delivery by accessing the device.

The agency issued a cybersecurity risk alert for the Medtronic MiniMed 600 Series insulin pump system, which has several components including an insulin pump and a blood glucose meter that communicate wirelessly.

The FDA said it was possible for an unauthorized person to gain access to a pump while it was pairing with other system components, but so far, it was not aware of any reports related to this cybersecurity vulnerability.

The insulin pumps are sold through Medtronic's diabetes segment, which brought in $2.41 billion in sales in 2021 and accounted for 8% of the company's total revenue.

Medtronic also warned users about the risks and made recommendations including asking them to permanently turn off the "Remote Bolus" feature on the pump, not share device's serial number with unauthorized personnel or conduct any connection linking of devices in a public place.

The company said hackers, however, cannot gain access to the device through internet.

The FDA said it was working with Medtronic to identify, communicate and prevent adverse events related to this risk.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)


More Related News

U.S. FDA declines to approve Y-mAbs
U.S. FDA declines to approve Y-mAbs's pediatric cancer drug

Y-mAbs said it is assessing the implications of the Food and Drug Administration's complete response letter (CRL) and the company's plans for the drug's development program. The FDA's decision follows a unanimous vote by its advisers in October against the drug, omburtamab, to treat neuroblastoma due to insufficient evidence that it improves overall survival. "We are disappointed but not surprised based on the outcome of the (FDA advisory panel) meeting," interim Chief Executive Officer Thomas Gad said in a statement.

U.S. FDA approves Rigel Pharma
U.S. FDA approves Rigel Pharma's treatment for a type of leukemia

The Food and Drug Administration approved the drug, which will be sold under the brand Rezlidhia, for the treatment of a type of cancer of the blood and bone marrow called acute myeloid leukemia in patients with a susceptible genetic mutation. Approval for the oral drug was supported by data from the company's mid-stage study, which showed a 35% rate for complete remission of the cancer with a complete or partial recovery in blood count. Rezlidhia will be the company's second treatment to get approval from the FDA after Tavalisse for a rare bleeding disorder called immune thrombocytopenic purpura.

Use of drugs for weight loss causes supply shortage
Use of drugs for weight loss causes supply shortage

Dramatic stories about weight loss using popular drugs are trending on social media. People who need the drugs for other health issues now face shortages.

FDA likely to end blanket ban on sexually active gay men donating blood
FDA likely to end blanket ban on sexually active gay men donating blood

Under current federal rules, men cannot donate blood if they have had sex with another man in the last three months.

FDA clears 1st fecal transplant treatment for gut infection
FDA clears 1st fecal transplant treatment for gut infection

U.S. officials have approved the first pharmaceutical-grade version of the so-called fecal transplant procedures that doctors have increasingly used against hard-to-treat intestinal infections. The Food and Drug Administration on Wednesday approved Rebyota for adults who have trouble fighting off infections with Clostridium difficile, commonly referred to as C. diff, a bacteria that causes nausea, cramping and diarrhea. For more than a decade, some U.S. doctors have used stool samples from healthy donors to treat the condition.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply


Top News: Health